119 results match your criteria: "Nakadori General Hospital[Affiliation]"

Left atrial appendage closure is widely performed in cardiac surgery to prevent intracardiac thrombus in patients with atrial fibrillation. Herein, we report the surgical case of an 80-year-old man whose left atrial appendage became aneurysmic long after undergoing suture exclusion. At the age of 67, he underwent mitral valve annuloplasty and left atrial appendage suture exclusion for mitral regurgitation and chronic atrial fibrillation at our institution.

View Article and Find Full Text PDF

Background: Spontaneous anterior interosseous nerve (AIN) palsy is characterized by the sudden onset of upper limb pain followed by weakness of muscles mainly innervated by the AIN. Although this palsy is conventionally treated conservatively, interfascicular neurolysis to release hourglass-like fascicular constrictions has been recommended. The present study aimed to establish the clinical characteristics and treatment strategy for this condition.

View Article and Find Full Text PDF

Diet-related cardiometabolic diseases and inflammatory bowel disease, common previously in Western countries, are global problems. We hypothesized that inflammatory bowel disease is a lifestyle disease primarily mediated by the current Western diet. We report here the simultaneous onset of ulcerative colitis and autoimmune pancreatitis, a rare systemic complication of inflammatory bowel disease, 2 months after acute myocardial infarction in a patient with type 2 diabetes.

View Article and Find Full Text PDF

Isolated adrenocorticotropic hormone deficiency (IAD) is a rare pituitary disorder that can cause adrenal insufficiency. However, due to its nonspecific symptoms, its diagnosis is often difficult and may be delayed. Patients with IAD require lifelong glucocorticoid (GC) replacement therapy.

View Article and Find Full Text PDF
Article Synopsis
  • FOLFOXIRI plus bevacizumab is a first-line chemotherapy for metastatic colorectal cancer, but is rarely used due to severe side effects, with limited real-world efficacy and safety data available.
  • A study analyzed clinical data from 104 patients, finding that 63% required dose reductions and that treatment discontinuation was primarily due to toxicities, with 45% completing the planned therapy cycles.
  • Results showed promising outcomes with a median progression-free survival of 12.8 months and overall survival of 27.9 months, along with a high disease control rate of 98.9%, and no treatment-related deaths reported.
View Article and Find Full Text PDF

Background: We assert that the ubiquitous environmental factor in inflammatory bowel disease (IBD) is our westernized diet. Therefore, all of our newly diagnosed patients were admitted to experience a plant-based diet (PBD). In the present study, we investigated the efficacy of a PBD in pregnant women with IBD.

View Article and Find Full Text PDF

Background: The safety and feasibility of using 1-month dual antiplatelet therapy (DAPT) followed by P2Yinhibitor monotherapy for patients after percutaneous coronary intervention (PCI) with thin-strut biodegradable polymer drug-eluting stents (BP-DES) in daily clinical practice remain uncertain.

Methods and results: The REIWA region-wide registry is a prospective study conducted in 1 PCI center and 9 local hospitals in northern Japan. A total of 1,202 patients who successfully underwent final PCI using BP-DES (Synergy: n=400; Ultimaster: n=401; Orsiro: n=401), were enrolled in the registry, and received 1-month DAPT followed by P2Yinhibitor (prasugrel 3.

View Article and Find Full Text PDF
Article Synopsis
  • Atypical femoral fractures (AFF) involve low-energy breaks in specific areas of the femur, and even after healing, there's a risk of similar fractures in the opposite leg.
  • The study analyzed 111 femurs from 104 patients to identify factors affecting the likelihood of complete fractures in the contralateral femur, categorizing them into groups based on their fracture status.
  • Key findings included that thicker lateral cortical bone and thigh pain indicated worse outcomes, while using eldecalcitol and previous bisphosphonate or denosumab treatments were protective against future complete fractures.
View Article and Find Full Text PDF

Eclipsed mitral regurgitation is a relatively new disease concept reported in recent years, of which is not fully elucidated. A 73-year-old female had repeated episodes of heart failure of unknown cause. During cardiac catheterization and echocardiography performed, mitral regurgitation suddenly worsened and improved in a few minutes.

View Article and Find Full Text PDF

The region behind the coronary calcium could not be visualized by intravascular ultrasound (IVUS) because of acoustic shadow. However, some pathological studies have shown that IVUS delineated the vessel border behind thin coronary calcium sheets. This study aimed to reveal whether recent IVUS can visualize the region behind thin coronary calcium sheets.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to evaluate the effectiveness and safety of Capecitabine plus oxaliplatin (CapeOX) as a first-line treatment for advanced gastric cancer in patients aged 70 years and older.
  • The trial included 108 chemotherapy-naive patients, who were given either the original or reduced doses of CapeOX, with overall survival (OS) being the primary measurement.
  • Results showed a median OS of 12.9 months, with some patients experiencing significant side effects, mainly neutropenia and anemia, indicating that CapeOX is a viable treatment option for older patients with advanced gastric cancer.
View Article and Find Full Text PDF

Background: Little is known about the biweekly combined use of cetuximab and chemotherapy as second-line treatment of metastatic colorectal cancer (mCRC). Recently, DNA methylation status has been reported to be a new possible predictor of the efficacy from the anti-epidermal growth factor receptor (EGFR) antibody treatment. The purpose of this study was to examine the efficacy and safety of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as a second-line treatment for exon 2 wild-type mCRC.

View Article and Find Full Text PDF

Background: T-cell acute lymphoblastic leukaemia has distinct biological characteristics and a poorer prognosis than B-cell precursor acute lymphoblastic leukaemia. This trial aimed to reduce the rate of radiation and haematopoietic stem-cell transplantation (HSCT) while improving outcomes by adding nelarabine, intensified L-asparaginase, and protracted intrathecal therapy in the Berlin-Frankfurt-Münster (BFM)-type treatment.

Methods: In this nationwide, multicenter, phase 2 trial, we enrolled patients with newly diagnosed T-cell acute lymphoblastic leukaemia (age <25 years at diagnosis) conducted by Japan Children's Cancer Group and Japan Adult Leukemia Study Group.

View Article and Find Full Text PDF
Article Synopsis
  • The study aims to assess the safety and effectiveness of FOLFIRI combined with aflibercept (AFL) as a second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are resistant to prior treatments involving anti-EGFR antibodies.
  • The main goal is to evaluate the 6-month progression-free survival (PFS) rate, with secondary goals including overall survival, response rates, and potential adverse effects, based on a sample size of 41 participants.
  • This research is necessary due to the lack of clinical trial data specifically for mCRC patients who have failed anti-EGFR therapy, highlighting the need for a prospective study to fill this knowledge gap.
View Article and Find Full Text PDF

Objectives: Osteoporosis patients with fragility fractures and vertebral deformities have impaired quality of life (QOL). The phase angle, an index calculated from bioelectrical impedance analysis (BIA) measurements, has been reported to be related to clinical outcomes, mortality, and QOL in various diseases. We aimed to investigate the relationship between the phase angle and QOL in patients with postmenopausal osteoporosis.

View Article and Find Full Text PDF

The patient is a 62-year-old man. He was referred to our hospital from a nearby clinic with a complaint of chest and back pain, and was urgently admitted with a diagnosis of Stanford type A (Debakey typeⅢbR) acute aortic dissection. During the course of his treatment, he developed a urinary tract infection caused by methicillin-resistant Staphylococcus aureus (MRSA).

View Article and Find Full Text PDF
Article Synopsis
  • * During surgery for the aortic dissection, the medical team also performed mitral valve replacement using a bioprosthetic valve due to worsened mitral regurgitation.
  • * The surgery went smoothly without complications, and the patient was able to leave the hospital on foot after rehabilitation, demonstrating the benefits of simultaneous surgical intervention.
View Article and Find Full Text PDF

Introduction Incorporation of a plant-based diet was effective in both induction and short-term relapse prevention in Crohn's disease. Ten-year long-term relapse-free rates in Crohn's disease are around 10% to 23%. Objective We investigated whether infliximab and plant-based diet as first-line therapy enhance the long-term relapse-free rate in patients with Crohn's disease.

View Article and Find Full Text PDF

Background: Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer.

Materials And Methods: Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included.

View Article and Find Full Text PDF

Background: An optimal treatment strategy using oxaliplatin and bevacizumab for metastatic colorectal cancer has not been defined. We investigated whether the sequential treatment using fluoropyrimidines with bevacizumab followed by the addition of oxaliplatin at first progression was better than a combination treatment using fluoropyrimidines and oxaliplatin with bevacizumab.

Methods: In the sequential treatment, the escalation from fluoropyrimidines plus bevacizumab to fluoropyrimidines plus oxaliplatin with bevacizumab was recommended in case of progressive disease.

View Article and Find Full Text PDF

Introduction: Combination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) has become one of the standard treatments for metastatic pancreatic cancer. However, the use of FOLFIRINOX requires prolonged infusion. Therefore, we planned to develop a new combination chemotherapy regimen with oxaliplatin, irinotecan and S-1 (OX-IRIS) for advanced pancreatic cancer.

View Article and Find Full Text PDF

Background: Safety of combination chemotherapy using platinum and fluorouracil has not been evaluated adequately for advanced gastric cancer (AGC) in elderly patients.

Patients And Methods: We initiated a phase II study to evaluate the efficacy and safety of capecitabine plus oxaliplatin (CapeOX) as first-line therapy for patients with AGC aged ≥70 years. Planned assessment of toxicity was made upon recruitment of the first 20 patients.

View Article and Find Full Text PDF

Background: We determined the usefulness and prognostic ability of the renal risk score (RRS), proposed in Europe, for Japanese patients with antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN) and high myeloperoxidase (MPO)-ANCA positivity; these aspects remain to be verified.

Methods: This retrospective study was conducted on 86 Japanese patients with new, biopsy-confirmed AAGN. We calculated the RRS and analyzed the relationship between this classification, and clinicopathological features and prognosis.

View Article and Find Full Text PDF

Background/aim: This phase II study assessed the efficacy of capecitabine plus cisplatin in patients with advanced gastric cancer refractory to adjuvant S-1.

Patients And Methods: This single-arm, open-label, multicenter, phase II study was conducted by Tohoku Clinical Oncology Research and Education Society (T-CORE) in Japan. Patients aged ≥20 years with advanced HER2-negative gastric cancer that was refractory to S-1 were enrolled.

View Article and Find Full Text PDF

Purpose: Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in patients with gastrointestinal cancer.

View Article and Find Full Text PDF